Lilly Ventures

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Nimbus Therapeutics is a biotechnology company designing small molecule compounds targeted at various diseases. It utilizes the chemical simulation computational platform built by co-founder Schr&ouml;dinger Inc., which incorporates artificial intelligence and machine learning, and co-develops drugs by partnering with pharma companies. Its pipeline includes programs in metabolic diseases, cancer, and immune-inflammatory disorders.&nbsp;
 
 
 As of March 2024, the company was developing five targets, of which one is in the clinical stage, two are in the preclinical stage, and others remain at a discovery stage. The company initiated investigational new drug (IND)-enabling studies on two novel agents in 2022.
 
 
 Takeda Pharmaceuticals acquired Nimbus Therapeutics&rsquo;s fully owned subsidiary, Nimbus Lakshmi, and its tyrosine kinase 2 (TYK2) (intracellular enzyme) program 
 <a href="https://sp-edge.com/updates/16314">
 in February 2023
 </a>
 . Following the acquisition, Nimbus&rsquo; drug candidate, NDI-034858, for psoriasis was renamed to &ldquo;TAK-279.&rdquo;&nbsp;
 
 
 Key customers and partnerships
 
 
 Nimbus Therapeutics&rsquo;&nbsp; pharma partners include Roche&rsquo;s Genentech, Celgene, and Gilead.
 
 In 
 <a href="https://sp-edge.com/updates/24983">
 December 2023
 </a>
 , Nimbus Therapeutics partnered with Anagenex to discover small-molecule drugs for various complex targets. Further, in October 2022, the company partnered with Eli Lilly to progress the development of novel targeted therapies that activate AMPK to potentially treat a broad range of metabolic disorders.
 
 
 Funding and financials
 
 
 In September 2023, the company raised USD 210 million in a 
 <a href="https://sp-edge.com/updates/21624">
 private funding round
 </a>
 co-led by GV (Google Ventures) in September 2023 to advance Nimbus Therapeutics' pipeline of drugs for various disorders. 
 
</div>

<div>
 
 BioAge Labs is a biotechnology company that develops therapies to treat aging and aging-related diseases with the aim of extending the human lifespan. It has developed a systems biology and machine learning platform to leverage its own datasets (collected from human blood samples and medical records) to identify and map the key biological pathways that impact human longevity.
 
 
 As of March 2024, the company&rsquo;s pipeline consisted of three drug candidates. Its lead candidate, BGE-105, also known as azelaprag, is a Phase II clinical-stage therapy that activates apelin/APJ signaling to treat muscle aging and helps older people recover from surgery faster (including muscle regeneration and repair). BGE-100 is a preclinical-stage oral drug targeted at chronic inflammasome activation associated with aging. BGE-100 is claimed to be potent and brain penetrant, with the ability to address a range of neurodegenerative conditions driven by neuroinflammation.
 
 
 Key customers and partnerships
 
 
 BioAge Labs has entered several key partnerships. These include partnerships with 1) Eli Lilly to test muscle regeneration therapy in combination with weight loss drug tirzepatide (
 <a href="https://www.fiercebiotech.com/biotech/lilly-help-bioage-test-muscle-regeneration-therapy-combo-weight-loss-drug-tirzepatide">
 October 2023
 </a>
 ), 2) Age Labs to perform multi-omics analyses on samples and health records from the Nord-Tr&oslash;ndelag Health Study (HUNT) biobank (August 2022), and 3) Amgen to obtain a license for Amgen&rsquo;s APJ agonist (BGE-105) (
 <a href="https://www.businesswire.com/news/home/20210414005118/en/BioAge-Signs-Exclusive-Agreement-With-Amgen-To-Develop-and-Commercialize-Amgen%E2%80%99s-Phase-1-APJ-Agonist-To-Treat-Diseases-of-Aging">
 April 2021
 </a>
 ).&nbsp;
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/26578">
 February 2024
 </a>
 , BioAge Labs secured USD 170 million in a Series D funding round led by Sofinnova Investments with the participation of new investors like Longitude Capital, RA Capital, Cormorant Asset Management, and existing investor Andreessen Horowitz. The funds were expected to be used to advance Phase II clinical development of azelaprag. 
 
</div>

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

<div>
 
 Sutro Biopharma is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Its key product candidate is luveltamab tazevibulin (luvelta), a folate receptor alpha (FolR&alpha;)-targeting ADC. Luvelta utilizes Sutro's proprietary cell-free XpressCF platform to enable site-specific conjugation and incorporation of both a cytotoxin and immunostimulatory component.
 
 
 
 
 Luvelta is currently being evaluated in multiple clinical trials for the treatment of ovarian, endometrial, lung, and rare pediatric cancers that express FolR&alpha;. In January 2024, compelling anti-leukemic activity was demonstrated with luvelta in relapsed/refractory pediatric patients with CBF/GLIS acute myeloid leukemia (AML). Part two of the REFR⍺ME-O1 registrational trial for platinum-resistant ovarian cancer is now enrolling patients. Additional trials are planned to begin in 2024, including a Phase 2 study in non-small cell lung cancer and a registration-enabling pediatric CBF/GLIS AML study (REFR⍺ME-P1).
 
 
 
 
 Sutro is utilizing its cell-free XpressCF and other proprietary technologies to build a pipeline of next-generation ADCs and biotherapeutics across multiple disease areas. The company has active collaborations with partners like Astellas, Merck, BMS, and Vaxcyte, generating over USD 854 million in payments through 2023.
 
 
 
 
 Key customers and partnerships
 
 
 
 
 
 In June 2022, Sutro entered into a worldwide strategic collaboration and licensing agreement with Astellas focused on the discovery and development of novel immunostimulatory ADCs (iADCs) enabled by Sutro's technology. The deal included USD 90 million upfront, up to USD 422.5 million in potential milestones per product candidate, and royalties.
 
 
 
 
 Sutro is also collaborating with Merck on MK-1484, a biologic in clinical trials as a monotherapy and in combination with pembrolizumab for solid tumors. With Bristol Myers Squibb, Sutro is developing CC-99712, a BCMA-targeting ADC in trials for multiple myeloma.
 
</div>

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, developed the first radioactive diagnostic agent approved by the US Food and Drug Administration (FDA) for imaging tau neurofibrillary tangles on positron emission tomography (PET) scans. The F-18 flortaucipir tracer, marketed under the name Tauvid, helps clinicians estimate the density and distribution of tau tangles in the brains of adults with cognitive impairment being evaluated for Alzheimer's disease.
Tauvid works by binding to tau proteins that form neurofibrillary tangles, which are a hallmark of Alzheimer's disease along with amyloid plaques. Previously, doctors could only diagnose Alzheimer's neuropathologically by identifying both plaques and tangles in the brain after death. With Tauvid, physicians can now visualize and assess tau pathology in living patients through PET imaging.
The FDA's approval of Tauvid in May 2020 was supported by two clinical studies evaluating the agent's safety and effectiveness. These studies demonstrated that readers interpreting Tauvid PET scans had a high probability of accurately detecting tau pathology and an average-to-high probability of correctly identifying patients without tau pathology.

Bringing Life-Saving Biologics to More Patients

Biosimilars

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer treatment. The company's strategy revolves around building a leading immuno-oncology franchise funded by cash generated from its portfolio of FDA-approved therapeutics. Coherus markets several biosimilar products in the US, including UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
In July 2023, Coherus launched YUSIMRY at a list price of USD 995 per carton for two 40 mg/0.8 mL autoinjectors, representing a discount of more than 85% compared to Humira. This pricing strategy aims to improve patient access to adalimumab treatment by offering significant cost savings. YUSIMRY is indicated for various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Coherus is also developing toripalimab, an anti-PD-1 antibody, for the US and Canadian markets through a licensing agreement with Shanghai Junshi Biosciences Ltd. A Biologics License Application (BLA) for toripalimab in combination with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma was under FDA review.
In March 2024, Coherus reported net revenue of USD 91.5 million for Q4 2023 and USD 257.2 million for the full year 2023, driven by sales of UDENYCA and CIMERLI. However, the company faced challenges, including a net loss of USD 79.7 million in Q4 and USD 237.9 million for the full year 2023. To address these challenges, Coherus initiated a workforce reduction of 30% to streamline operations and focus on oncology.

Longevity Tech

BioAge Labs is a biotech company that develops therapies to treat aging and aging-related diseases. It has developed a systems biology and machine-learning platform to leverage its datasets (collected from human blood samples and medical records) to identify and map the key biological pathways that impact human longevity. The company has one clinical-stage drug candidate in its portfolio. BGE-105 is a Phase II clinical-stage therapy that activates apelin/APJ signaling to treat muscle aging and helps older people recover from surgery faster (including muscle regeneration and repair). The drug candidate was licensed from Amgen in April 2021. BGE-100 is a preclinical-stage oral drug targeted at chronic inflammasome activation associated with aging. BGE-100 is claimed to be potent and brain penetrant, with the ability to address a range of neurodegenerative conditions driven by neuroinflammation. Key customers and partnerships In August 2022, BioAge Labs partnered with Age Labs, a diagnostic company that develops tests for the early detection of age-related diseases. Under the partnership, BioAge Labs was to perform multi-omics analyses on samples and health records from the Nord-Trøndelag Health Study (HUNT) biobank collected from over 100,000 northern European volunteers over more than 25 years of aging and use machine-learning methods to explore molecular mechanisms of healthy human longevity. The agreement grants the company exclusive access for the purpose of drug discovery to data generated by the partnership. Funding and financials The company raised an undisclosed amount in a Series C funding round in December 2020. The funds were to be used to build its drug discovery platform and advance the clinical trials of BGE-117.

RNA Therapeutics

Evox Therapeutics is a privately held biotechnology company based in Oxford, UK, specializing in exosome therapeutics. The company focuses on developing a new class of therapeutics for the treatment of severe rare diseases by harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes. Evox's proprietary DeliverEX technology platform engineers exosomes to facilitate drug delivery to organs of interest, including the brain and central nervous system.The company's exosome-based drugs aim to address limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics. Evox's technology enables safe, non-immunogenic repeated delivery to cells and tissues that are currently challenging to reach using other drug delivery methods. The company has developed an exosome engineering platform capable of delivering a wide range of genetic medicines, including genome editors, RNAi, and mRNA.Evox has made significant advancements in exosome manufacturing and purification processes. The company has been granted multiple patents covering key purification processes and methods of exogenous loading. As of May 2023, Evox's patent portfolio contained more than 100 granted patents across key jurisdictions, covering various aspects of designing, developing, and manufacturing exosome-based drugs.In June 2023, Evox acquired Codiak Biosciences' engEx-AAV technology platform, which enables active loading of adeno-associated virus (AAV) into exosomes. This technology has demonstrated improved AAV delivery, increased expression in preclinical models, and the ability to shield AAVs from neutralizing antibodies.

Therapeutics that target specific areas/tissues to minimize treatment side effects.

Tissue Targeting Therapeutics

Evox Therapeutics is a biotechnology company specializing in exosome therapeutics. The company utilizes its proprietary DeliverEX technology to engineer exosomes for drug delivery to specific organs, including the brain and central nervous system. Evox's approach aims to overcome limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe, non-immunogenic repeated delivery to cells and tissues that are challenging to reach with other drug delivery technologies.
The company's technology focuses on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop a new class of therapeutics for treating severe rare diseases. Evox's intellectual property portfolio includes more than 100 granted patents across key jurisdictions, covering various aspects of exosome-based drug design, development, and manufacturing. In May 2023, Evox was granted a US patent for a method of purifying engineered exosomes using ultrafiltration and size-based separation steps, which is widely used in exosome therapeutics.
In June 2023, Evox acquired Codiak Biosciences' engEx-AAV technology platform, which enables active loading of adeno-associated virus (AAV) into exosomes. This technology has demonstrated improved AAV delivery, increased expression breadth in preclinical models, and shielding of AAVs from neutralizing antibodies. The acquisition aligns with Evox's strategy to enhance exosome-mediated delivery for genetic medicines such as gene therapy and genome editors.

BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.

IpiNovyx Bio is a biopharmaceutical company developing immunoproteasome-modulating therapeutics to treat autoimmune and inflammatory diseases. It helps create inhibitors to selectively target the immunoproteasome and modulate specific immune cell types for patients to recover from autoimmune and inflammatory diseases and improve their health.

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.

Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.

Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical-stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. Nimbus Therapeutics designs highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer, and immune-inflammatory disorders.

Cavion is a clinical stage pharmaceutical company committed to providing patients with therapies for cancer and neurologic diseases through the development of drugs that selectively inhibit the T-type calcium channel (Cav3).  Built on the discovery by Cavion’s founders that ion channels are a target for the treatment of solid tumor cancers, they were the first company to invent therapies engaging Cav3 for the treatment of solid tumors. The innovative idea of treating pathologically proliferating, non-electrically excitable cells by targeting an ion channel has already shown success in preclinical studies and is being tested in Phase 1 safety and dose-finding clinical trials in brain cancer. Their technology is intended to magnify the effects of combined chemotherapy, radiation, and targeted therapies for all solid tumor cancers.  Their neurology program uses superior chemistry and clinical expertise to deliver a novel class of drugs that will provide patients with treatments for neurologic diseases.  While Cav3 is an established target in neurology, particularly neuropathic pain, Cavion is working to bring the first non-addictive, non-opioid T-type calcium channel antagonist to patients with neuropathic pain. Given that Cav3 plays a role in numerous pathologic conditions, Cavion is simultaneously developing therapies for additional neurologic afflictions such as essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome.

Symic Biomedical is a developer of matrix regulator therapeutics designed to affect matrix degradation and structure. The company's therapeutics bind to targets in the matrix, damaged in response to injury or because of disease, to inhibit pathological inflammatory responses, enabling clinicians to investigate applications in the areas of fibrosis, oncology and diseases of the central nervous system.

Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that address rare genetic diseases.

Lysosomal Therapeutics is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Their strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies.

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.

Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell.

Viamet Pharmaceuticals discovers and develops ''best-in-class'' inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

Numerate is a group of cutting-edge scientists and engineers trying to solve very difficult problems at the interface of data science, machine learning, cloud scale analytics and medicinal chemistry.  We have developed a computational platform that can predict how a potential drug will behave in the lab and the body.  We use this platform to process large spaces of chemistry while searching for therapies for some of the world’s most important diseases, such as, obesity, heart failure, Alzheimer’s, and Huntington’s disease. Our platform makes the drug development process cheaper, faster, and results in higher success rates than traditional approaches.

Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.

Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases.   The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers.  FORMAâ€™s approach to accessing such high value drug targets, many of which pose significant challenges to conventional discovery approaches, is rooted in the concerted integration of its innovative drug discovery technologies and oncology expertise, enabling screening, discovery and rational development of a generation of small molecule drug candidates with cellular mechanisms of action. FORMA is building a pipeline of therapeutics directed at Achilles heels in human cancers, such as key targets associated with cancer stem cells, tumor cell metabolism, programmed cell death or epigenetic disease mechanisms.  FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.

MedManage is an online drug sampling provider. The company's Samples On Demand(TM) service connects pharmaceutical manufacturers' brands with their customers through a network of physician portals which provides users near ubiquitous access to medication samples.

Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also develops SNX-1012, a product for oral mucositis in solid tumor patients. Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.

InnoCentive is the global leader in crowdsourcing innovation problems to the world’s smartest people who compete to provide ideas and solutions to important business, social, policy, scientific, and technical challenges.  Their global network of millions of problem solvers, proven challenge methodology, and cloud-based innovation management platform combine to help their clients transform their economics of innovation through rapid solution delivery and the development of sustainable open innovation programs.  For more than a decade, leading organizations such as AARP Foundation, Air Force Research Labs, Booz Allen Hamilton, Cleveland Clinic, Eli Lilly & Company, EMC Corporation, NASA, Nature Publishing Group, Procter & Gamble, Scientific American, Syngenta, The Economist, Thomson Reuters, and several government agencies in the U.S. and Europe have partnered with InnoCentive to rapidly generate innovative new ideas and solve problems faster, more cost effectively, and with less risk than ever before.

GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.

Remon Medical Technologies is a development-stage company focused on communication technology for medical device applications. It offers RemonCHF, a device that monitors the hemodynamic status of patients with congestive heart failure; and RemonAAA, a device that monitors pressure following an endograft procedure in AAA patients. The company is based in Caesarea, Israel.

Founded out of Yale University, CGI (formerly Cellular Genomics Inc.) began operations in 2000.  CGI, in conjunction with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), utilized a unique chemical-genetics approach known as “ASKA” (Analog Sensitive Kinase Alleles) to understand kinase function.   CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics (DMPK) expertise.  Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds (all compounds designed and synthesized by CGI).  To date, CGI has been awarded 8 U.S. patents covering its novel collection of kinase inhibitors.  Moreover, all three of CGI’s drug discovery and development programs are based on hits obtained from CGI’s library.

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California

Nanostream Inc. provides products and services for pharmaceutical and biotech companies.

NexCura applications and custom services are made available through an application service provider (ASP) model on Web sites and are used to collect comprehensive clinical data and facilitate communication between patients and their physicians. The aggregate data They collect provides direct value to healthcare organizations, pharmaceutical companies, physicians, and patients.

Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe.  Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.

Lilly Ventures

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless